FSRH New Product Review: Kyleena® 19.5 mg Intrauterine Delivery System (January 2018, amended March 2019)
File size 309KB | Date: 04 March 2019
Date: 29 Jan 2018
Type: FSRH News and Information
Kyleena® (Bayer plc) is a levonorgestrel (LNG) intrauterine system (IUS) newly launched in the UK that is licensed for contraceptive use for 5 years. The CEU has produced a new product review for Kyleena which summarises the key differences in the product and clinical characteristics between Kyleena and other LNG-IUS available in the UK.
This new product review is intended to inform health professionals and is not a guidance document. For further information about medical eligibility, health benefits, side effects and health risks associated with use of LNG-IUS, please refer to FSRH guidance on intrauterine contraception at the link below.
The new product review for Kyleena can be found at the link below.